Description
Wikijet (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.
Supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, and available across the complete six-strength approved dose escalation range: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg from the tolerability initiation step through the maximum approved tirzepatide maintenance dose manufactured by Aristopharma Ltd., Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity, the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists semaglutide, liraglutide, dulaglutide, exenatide that engage only the GLP-1 receptor.
The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo, with 87.4% of patients achieving HbA1c below 7.0% versus 19.9% with placebo, without hypoglycemia as monotherapy; at the 10 mg and 15 mg steps available in Wikijet, HbA1c reductions reach 2.01% and 2.30% respectively outcomes unmatched by any other approved antidiabetic agent.
In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide demonstrated statistically significant superiority in both HbA1c reduction and body weight reduction at all doses studied, establishing tirzepatide as the most efficacious approved injectable antidiabetic agent tested against an active comparator in a prospective randomized trial. Searching for Wikijet Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.
Basic Product Information of Wikijet (Tirzepatide)
| Brand Name | Wikijet (Tirzepatide) |
| Product Name | Wikijet |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM) |
| Formulation | Subcutaneous Injection (Pre-filled Syringe) |
| Available Strengths | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg tirzepatide per pre-filled syringe the complete six-step approved dose escalation range, from the 2.5 mg tolerability initiation dose through the 15 mg maximum approved tirzepatide maintenance dose |
| Available Pack Size | 1 pre-filled syringe per box |
| Recommended Dose & Administration | Initiation dose (Weeks 1–4): 2.5 mg subcutaneously once weekly. This is a tolerability initiation dose, not the therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 Therapeutic (Week 5 onward): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Step 2 (if additional glycemic control required): Increase to 7.5 mg subcutaneously once weekly after at least 4 weeks at 5 mg. Step 3: Increase to 10 mg subcutaneously once weekly after at least 4 weeks at 7.5 mg, if glycemic and weight targets are not met. Step 4: Increase to 12.5 mg subcutaneously once weekly after at least 4 weeks at 10 mg. Step 5 Maximum Dose: Increase to 15 mg subcutaneously once weekly after at least 4 weeks at 12.5 mg; 15 mg is the highest approved tirzepatide maintenance dose and is available as a procurable pre-filled syringe in the Wikijet range from Aristopharma Ltd. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Wikijet may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater); use with caution in severe renal impairment. No dose adjustment is required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Wikijet therapy. |
| Primary Indications | Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting Wikijet therapy. |
| Manufacturer | Aristopharma Ltd., Bangladesh |
| Country of Origin | Bangladesh |
| SKU | tirzepatide-wikijet |
| Categories | Diabetes Medicines; Tirzepatide Medicines |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Wikijet is manufactured by Aristopharma Ltd. in Bangladesh and is supplied through Mediaid Pharmacy for international procurement. |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Wikijet pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
How Wikijet (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes
Tirzepatide INN is a 39-amino acid acylated peptide that simultaneously agonizes two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This co-receptor mechanism the first approved in the antidiabetic drug class distinguishes tirzepatide as a “twincretin,” a dual incretin receptor agonist that activates two complementary glucose-lowering and weight-reducing signaling pathways within a single weekly injection.
Monoagonist GLP-1 receptor agonists such as semaglutide, liraglutide, dulaglutide, and exenatide activate only the GLP-1R; they cannot recruit the GIPR pathway. Wikijet (Tirzepatide) recruits both. GLP-1 is released by intestinal L cells following nutrient ingestion, driving glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from pancreatic alpha cells, gastric emptying delay to flatten postprandial glucose excursions, and hypothalamic satiety activation to reduce caloric intake.
GIP is released by K cells in the duodenum and proximal jejunum in response to dietary fat and carbohydrate, stimulating insulin secretion through a distinct cAMP signaling cascade in beta cells and modulating adipose tissue lipid partitioning and energy balance via GIPR-expressing adipocyte pathways. In type 2 diabetes mellitus (T2DM), both incretin axes are impaired: GLP-1 secretion is markedly attenuated post-meal, and residual GIP signaling fails to achieve a normal insulin secretory response in the insulin-resistant pancreatic beta cell. Tirzepatide’s dual receptor engagement addresses both deficits simultaneously reconstituting GIP and GLP-1 signaling within a single molecular entity that is dosed once per week.
The molecular architecture enabling tirzepatide’s dual agonism is a 39-amino acid peptide sequence with N-terminal structural homology to native GIP, incorporating optimized amino acid substitutions for balanced GIPR and GLP-1R affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This acylation achieves albumin binding exceeding 99%, shielding tirzepatide from N-terminal DPP-4 cleavage that degrades native GIP and GLP-1 within 1 to 2 minutes of portal circulation entry, and extends the elimination half-life to approximately 5 days underpinning Wikijet’s once-weekly subcutaneous injection convenience across all six dose steps, from the 2.5 mg initiation syringe through the 5 mg, 7.5 mg, 10 mg, 12.5 mg escalation steps and the 15 mg maximum dose syringe, each procurable as a separate unit from Mediaid Pharmacy.
Tirzepatide activates GIPR with potency approximately matching native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet produces GLP-1R-mediated pharmacological effects insulin secretion potentiation, glucagon suppression, gastric emptying delay, appetite reduction, body weight loss that equal or exceed those of optimized GLP-1 monoagonists in head-to-head clinical comparisons. The mechanistic explanation lies in receptor co-stimulation synergy: simultaneous GIPR and GLP-1R activation produces cAMP signaling in pancreatic beta cells from two independent receptor cascades, additive adipose tissue GIPR contributions to energy partitioning, and tissue-level amplification of the GLP-1R-mediated satiety signal by concurrent GIPR activation in hypothalamic circuits.
Pharmacokinetically, tirzepatide administered via the Wikijet pre-filled syringe reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours, achieves steady-state plasma exposure after 4 weeks of once-weekly dosing, and is cleared primarily through proteolytic peptide backbone degradation and fatty acid beta-oxidation with no dominant cytochrome P450 (CYP) metabolic pathway and no clinically meaningful accumulation with weekly dosing across the full renal function spectrum. The six-step Wikijet dose escalation architecture (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) enables the treating endocrinologist to calibrate glycemic efficacy, weight-reduction benefit, and gastrointestinal tolerability for each individual patient at every stage, within a single product range requiring no formulation switch. For the complete selection of diabetes medicines at Mediaid Pharmacy with worldwide shipping, browse the full specialty portfolio.
Wikijet (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Wikijet (Tirzepatide) is used as monotherapy when oral antidiabetic agents are not tolerated or contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing single-agent or combination therapy fails to achieve individualized HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines the appropriate patient candidacy, dose escalation schedule across the six Wikijet dose steps, and combination antidiabetic regimen based on HbA1c target, weight-reduction goal, cardiovascular risk profile, renal function, and individual gastrointestinal tolerability. |
| Dosing Schedule | Weeks 1–4 (Initiation): 2.5 mg subcutaneously once weekly tolerability initiation dose, not the therapeutic maintenance dose. Week 5 onward (Step 1 Therapeutic): 5 mg subcutaneously once weekly. After ≥4 weeks at 5 mg (Step 2): 7.5 mg subcutaneously once weekly, if additional glycemic control is required. After ≥4 weeks at 7.5 mg (Step 3): 10 mg subcutaneously once weekly, if glycemic and weight targets remain unmet. After ≥4 weeks at 10 mg (Step 4): 12.5 mg subcutaneously once weekly. After ≥4 weeks at 12.5 mg (Step 5 Maximum Dose): 15 mg subcutaneously once weekly; 15 mg is the highest approved tirzepatide maintenance dose and is procurable as a pre-filled syringe in the Wikijet range from Aristopharma Ltd. Inject subcutaneously into the abdomen, thigh, or upper arm; rotate sites each week. Administer at any time of day, with or without meals. |
| Common Adverse Reactions | The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical program are gastrointestinal: nausea (12 to 18% at 5 mg, with modest, dose-dependent increase at higher escalation steps), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during the dose initiation and early escalation phases and generally transient in nature. The 2.5 mg initiation dose protocol across Weeks 1 to 4 of Wikijet therapy is specifically engineered to reduce the frequency and severity of these gastrointestinal effects prior to advancing to the 5 mg therapeutic dose. Injection site reactions erythema, pain, bruising are reported in approximately 3 to 7% of patients; weekly site rotation minimizes their incidence. Hypoglycemia does not occur with Wikijet as monotherapy due to tirzepatide’s strictly glucose-dependent insulin secretion mechanism, which extinguishes the insulin secretory signal as plasma glucose normalizes; hypoglycemia risk increases when Wikijet is combined with a sulfonylurea or basal insulin, requiring dose reduction of those agents. Rare serious adverse reactions include acute pancreatitis (discontinue Wikijet immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Wikijet (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Wikijet therapy. |
| Drug Interactions | Narrow therapeutic index oral medications: Tirzepatide delays gastric emptying and may alter the Cmax and Tmax of concomitantly administered oral drugs. Particular caution applies to warfarin, cyclosporine, and digoxin. Oral contraceptives: When initiating Wikijet or escalating the dose at any step (2.5 mg to 5 mg, or any subsequent step), gastric emptying delay may transiently reduce peak contraceptive plasma concentrations; switch to non-oral contraception or add a barrier method for 4 weeks after starting Wikijet and for 4 weeks after each dose escalation. Warfarin and vitamin K antagonists: Monitor INR more frequently when initiating or dose-escalating Wikijet due to the potential pharmacokinetic effect on warfarin absorption. Sulfonylureas and basal insulin: Concomitant use with glimepiride, glibenclamide, insulin glargine, or insulin detemir increases hypoglycemia risk; reduce the sulfonylurea or insulin dose when initiating Wikijet in patients already on these agents. Other GLP-1 receptor agonists: Do not co-administer Wikijet (Tirzepatide) with semaglutide, liraglutide, dulaglutide, or exenatide; additive receptor agonism produces no established additional glycemic benefit and compounds gastrointestinal adverse effects. |
| Contraindications | Wikijet (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any excipient in the Wikijet formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. |
| Renal Impairment | No dose adjustment of Wikijet (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater). Use with caution in severe renal impairment (eGFR below 30 mL/min/1.73 m²); gastrointestinal adverse effects occurring during the early Wikijet escalation steps particularly nausea, vomiting, and diarrhea may precipitate dehydration and acute kidney injury in renally vulnerable patients, requiring closer monitoring, proactive hydration guidance, and serial renal function assessment. Consult the treating endocrinologist and nephrologist before initiating or escalating Wikijet in patients with advanced chronic kidney disease. |
| Pregnancy & Lactation | Wikijet (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. Insulin remains the preferred antidiabetic agent in pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Wikijet therapy; if pregnancy occurs or is planned, discontinue Wikijet and transition to insulin immediately under endocrinologist guidance. Breastfeeding is not recommended during Wikijet treatment; it is unknown whether tirzepatide is excreted in human breast milk and the risk to the nursing infant cannot be excluded. |
Who Should Use Wikijet (Tirzepatide)?
Wikijet (Tirzepatide) is indicated for adults with type 2 diabetes mellitus who require improved glycemic control as an adjunct to diet and exercise a population characterized by progressive insulin secretory failure, attenuated GIP and GLP-1 incretin responses, postprandial glucagon excess, and frequently co-occurring excess body weight. For this population, a once-weekly dual incretin receptor agonist covering the complete six-step dose escalation ladder delivers simultaneous glycemic and cardiometabolic benefits that oral antidiabetic agents and monoagonist injectable therapies cannot match.
First, adults with type 2 diabetes requiring substantial HbA1c reduction are the primary candidates for Wikijet. Patients presenting with baseline HbA1c above 8.5%, or needing reductions greater than 1.5% to achieve their individualized targets, derive the most benefit from tirzepatide’s twincretin mechanism and Wikijet’s stepwise escalation to 7.5 mg, 10 mg, 12.5 mg, and the 15 mg maximum dose. SURPASS-3 data (1,444 patients, 52 weeks, vs titrated insulin degludec) showed tirzepatide at 15 mg achieving 2.37% HbA1c reduction versus 1.34% with insulin degludec, without hypoglycemia as monotherapy evidence that the full dose range available in Wikijet delivers outcomes insulin cannot match on the same safety profile.
Second, adults with type 2 diabetes and significant overweight or obesity for whom body weight reduction is a co-primary clinical priority represent a population that benefits directly from Wikijet’s higher dose steps. In SURPASS-4 (2,002 high cardiovascular risk patients, 104 weeks), tirzepatide 15 mg produced a mean body weight reduction of 13.4 kg the dose available as the maximum syringe in Wikijet versus 2.5 kg with insulin glargine titrated to target (p<0.001), with simultaneous reductions in waist circumference, systolic blood pressure, triglycerides, and total cholesterol.
Third, adults with type 2 diabetes who have completed the 5 mg or 7.5 mg escalation steps on another tirzepatide product and require intensification beyond those doses benefit specifically from Wikijet’s unique ability to supply the 10 mg, 12.5 mg, and 15 mg steps in the same product range from Aristopharma Ltd., without requiring a product switch or a separate supplier.
Fourth, patients in whom minimizing hypoglycemia risk is clinically imperative those with hypoglycemia unawareness, driving or operating heavy machinery, with strict cardiovascular indications benefit from tirzepatide’s glucose-dependent insulin secretion mechanism across all six Wikijet dose steps. Endocrinology programs co-sourcing Wikijet with the broader specialty diabetes portfolio can browse the Mediaid Pharmacy injectable diabetes medicines range for worldwide delivery options.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Wikijet (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based specialty medicine supplier serving patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions with worldwide shipping. Wikijet (Tirzepatide), manufactured by Aristopharma Ltd. in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes in all six approved dose strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg with 1 pre-filled syringe per box, with pricing quotations, per-strength stock confirmation, complete product documentation, and end-to-end international delivery tracking provided for every order.
The pre-filled syringe format of Wikijet supports once-weekly self-injection without dose measurement, device assembly, or cartridge loading, simplifying procurement logistics, pharmacy dispensing, patient training, and injection technique instruction for diabetes centers and endocrinology programs managing patients across the full tirzepatide escalation pathway from a single product and a single supplier. Diabetes specialist centers managing patients through the complete Wikijet dose escalation ladder, endocrinology programs requiring the full tirzepatide subcutaneous injection strength range including 10 mg, 12.5 mg, and 15 mg dose steps, hospital pharmacy departments co-sourcing injectable antidiabetic medicines for inpatient and outpatient use, international distributors, and individual patients can reach the Mediaid Pharmacy team via WhatsApp, phone, or WeChat for stock availability, current per-strength pricing, and international delivery timelines by country.
Procurement teams consolidating Wikijet with other specialty diabetes or metabolic medicines can review the complete buy diabetes medicines online catalog at Mediaid Pharmacy before submitting a consolidated sourcing inquiry.
Why Choose Wikijet (Tirzepatide) from Mediaid Pharmacy?
Wikijet (Tirzepatide) delivers the highest clinically documented HbA1c reduction and body weight reduction of any approved injectable antidiabetic agent, a distinction established across the five-trial SURPASS Phase 3 program through tirzepatide’s twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation a pharmacological approach that no GLP-1 monoagonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin can replicate in a once-weekly subcutaneous injection. In SURPASS-2 (1,879 adults with T2DM, 40 weeks), tirzepatide at all doses demonstrated p<0.001 superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction; at the 15 mg maximum dose available in Wikijet, tirzepatide achieved 2.30% HbA1c reduction and 12.4 kg weight loss versus 1.86% and 5.7 kg with semaglutide 1 mg the largest glycemic and weight treatment differences observed against any active comparator in a prospective, randomized antidiabetic trial. In SURPASS-4 (2,002 high cardiovascular risk patients, 104 weeks vs insulin glargine), the 15 mg Wikijet dose delivered 2.37% HbA1c reduction and 13.4 kg weight loss versus 1.34% and 2.5 kg gain with insulin glargine.
Wikijet’s defining clinical and procurement advantage is the availability of all six approved tirzepatide dose strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg within a single product manufactured by Aristopharma Ltd., enabling every patient and every prescriber to navigate the complete FDA-approved tirzepatide escalation schedule without switching brands, suppliers, or formulations at any step. Diabetes centers sourcing patients across diverse stages of the tirzepatide escalation schedule some beginning at 2.5 mg initiation, others already at 10 mg intensification can fulfill the entire range from one procurement agreement.
The mandated 2.5 mg tolerability initiation protocol reduces early gastrointestinal treatment discontinuation, and with all six Wikijet doses procurable from a single source, the initiation, titration, and maximum-dose phases are logistically unified. The monotherapy hypoglycemia-free safety profile across all six Wikijet dose steps a direct result of glucose-dependent insulin secretion that automatically terminates as plasma glucose normalizes means Wikijet can be escalated to the 15 mg maximum dose without hypoglycemia dietary restrictions beyond standard diabetic care. Once-weekly dosing via the Wikijet pre-filled syringe eliminates the daily injection burden associated with liraglutide and the oral daily adherence requirements of SGLT2 inhibitors and DPP-4 inhibitors, supporting clinical adherence across the multi-month escalation period.
Wikijet, manufactured by Aristopharma Ltd. in Bangladesh, delivers tirzepatide INN the same active pharmaceutical ingredient as Mounjaro® in pre-filled syringes at all six approved strengths, available through Mediaid Pharmacy with worldwide shipping. To browse the complete Wikijet Tirzepatide product range at Mediaid Pharmacy and the full specialty diabetes medicines portfolio, contact the team for a consolidated quote.
Frequently Asked Questions About Wikijet (Tirzepatide)
What is Wikijet (Tirzepatide) used for?
Wikijet (Tirzepatide) is a dual GIP and GLP-1 receptor agonist a twincretin used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection via a pre-filled syringe, Wikijet is used as monotherapy when metformin or other oral agents are not tolerated or contraindicated, and as combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment does not achieve adequate HbA1c control. Wikijet works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022). Wikijet, manufactured by Aristopharma Ltd. in Bangladesh, is available through Mediaid Pharmacy with worldwide shipping to patients and diabetes specialist centers globally.
What is the generic name of Wikijet?
The generic name of Wikijet is tirzepatide INN. Wikijet is the brand name registered by Aristopharma Ltd. for tirzepatide manufactured in Bangladesh. It is formulated as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths the complete six-step approved escalation range supplied as 1 pre-filled syringe per box, supporting the once-weekly dosing schedule from the 2.5 mg tolerability initiation step through each escalation step to the 15 mg maximum dose as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Wikijet globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.
What is the difference between Wikijet (Tirzepatide) and Mounjaro® (Tirzepatide)?
Wikijet and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and commercialized by Eli Lilly and Company, approved by the U.S. FDA on May 13, 2022. Wikijet is manufactured by Aristopharma Ltd. in Bangladesh, supplied in pre-filled syringes in all six approved strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg covering the complete tirzepatide dose escalation ladder from initiation through maximum maintenance dose, with 1 pre-filled syringe per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centers and patients in regions where Mounjaro® is unavailable or cost-prohibitive. For the full portfolio of tirzepatide injection products at Mediaid Pharmacy, browse the complete collection.
How is Wikijet (Tirzepatide) administered?
Wikijet (Tirzepatide) is administered once weekly as a subcutaneous injection via the pre-filled syringe. Recommended injection sites include the abdomen (at least 5 cm from the navel), the thigh, and the upper arm; rotate sites with each weekly injection to minimize erythema, bruising, and local pain. Wikijet may be administered at any time of day, independently of meals. The approved escalation schedule begins at 2.5 mg once weekly for 4 weeks, then advances to 5 mg; subsequent dose escalations to 7.5 mg, 10 mg, 12.5 mg, and the 15 mg maximum dose each require a minimum 4-week interval at the preceding dose step. If a dose is missed and the next scheduled injection is more than 4 days away, administer the missed dose promptly and resume the weekly schedule. If the next dose is 4 days or fewer away, skip the missed dose; never administer two doses within 3 days of each other. Store Wikijet pre-filled syringes refrigerated at 2°C to 8°C until use. Confirm injection technique and the full escalation timeline with the prescribing endocrinologist before commencing Wikijet treatment.
What are the side effects of Wikijet (Tirzepatide)?
The most commonly reported side effects of Wikijet (Tirzepatide) are gastrointestinal: nausea (12 to 18% of patients at 5 mg, with dose-proportional modest increases at higher steps), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly arising during dose initiation and escalation and typically transient. The 2.5 mg initiation protocol for the first 4 weeks minimizes these effects before advancing to the 5 mg and subsequent doses. Injection site reactions erythema, bruising, and localized pain occur in approximately 3 to 7% of patients and are reduced by consistent weekly site rotation. Wikijet does not cause hypoglycemia as monotherapy; hypoglycemia risk increases when combined with sulfonylureas or basal insulin, requiring dose reduction of those agents. Rare but serious adverse reactions include acute pancreatitis (discontinue Wikijet immediately if pancreatitis is clinically suspected), anaphylaxis, angioedema, and acute gallbladder disease. Wikijet carries a boxed warning for thyroid C-cell tumors; instruct patients to report neck masses, hoarseness, dysphagia, or persistent dysphonia at any point during therapy. Always review the complete safety profile and contraindication list with the treating endocrinologist before initiating or continuing Wikijet.
Does Wikijet (Tirzepatide) cause weight loss?
Yes. Wikijet (Tirzepatide) produces clinically significant and dose-dependent body weight reductions in adults with type 2 diabetes, driven by dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to suppress appetite, gastric emptying delay that reduces the rate of postprandial caloric absorption, and adipose tissue GIPR engagement that modulates energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg produced mean weight reduction of 7.0 kg versus 0.7 kg with placebo. In SURPASS-4 (104 weeks vs insulin glargine), the 15 mg maximum dose available in Wikijet produced a mean weight reduction of 13.4 kg versus a 2.5 kg increase with insulin glargine titrated to target (p<0.001), accompanied by reductions in waist circumference, systolic blood pressure, triglycerides, and markers of insulin resistance. The stepwise availability of 10 mg, 12.5 mg, and 15 mg dose syringes in the Wikijet range allows the treating endocrinologist to titrate to the weight-reduction and glycemic response required for each patient. For the complete portfolio of diabetes medicines at Mediaid Pharmacy with worldwide shipping, browse the full specialty catalog.
How does Wikijet (Tirzepatide) compare to semaglutide for type 2 diabetes?
Wikijet (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents but operate through mechanistically different receptor pathways. Semaglutide is a GLP-1 monoagonist that activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates the GIPR and GLP-1R, adding a GIP receptor signaling arm that semaglutide cannot engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), all tirzepatide doses demonstrated p<0.001 superiority over semaglutide 1 mg in both HbA1c reduction and body weight reduction; at the 15 mg maximum dose available in Wikijet, tirzepatide achieved 2.30% HbA1c reduction and 12.4 kg weight loss versus 1.86% HbA1c reduction and 5.7 kg weight loss with semaglutide 1 mg. This dose-consistent superiority of tirzepatide over the most widely prescribed GLP-1 receptor agonist in a prospective, randomized, active-controlled trial is the definitive clinical differentiation of the twincretin class. The full range of tirzepatide subcutaneous injection products at Mediaid Pharmacy is available for worldwide shipping; contact the team for per-strength pricing and current stock.
What are the available strengths of Wikijet Tirzepatide?
Wikijet (Tirzepatide) manufactured by Aristopharma Ltd. is available in six pre-filled syringe strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, supplied as 1 pre-filled syringe per box. The 2.5 mg syringe covers the 4-week tolerability initiation phase. The 5 mg is the first therapeutic maintenance dose. The 7.5 mg, 10 mg, and 12.5 mg strengths are sequential dose intensification steps. The 15 mg syringe delivers the maximum approved tirzepatide maintenance dose. All six strengths are procurable as individual units from Mediaid Pharmacy, enabling diabetes specialist centers to supply the entire dose escalation sequence from a single product line. For stock confirmation, per-strength pricing, and international delivery, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.
Who manufactures Wikijet Tirzepatide?
Wikijet (Tirzepatide) is manufactured by Aristopharma Ltd., a pharmaceutical company based in Bangladesh. Aristopharma Ltd. produces Wikijet as a subcutaneous injection in pre-filled syringes across all six approved tirzepatide dose strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg containing tirzepatide INN as the active pharmaceutical ingredient. Mediaid Pharmacy, a Dhaka-based specialty medicine supplier, distributes Wikijet by Aristopharma Ltd. globally with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, and hospital pharmacy departments. The originator reference brand for tirzepatide is Mounjaro® (Eli Lilly and Company, USA; FDA-approved May 13, 2022).
Can I order Wikijet (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Aristopharma Ltd. Wikijet (Tirzepatide) pre-filled syringes in all six strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or by email at info@mediaidpharmacy.com for per-strength pricing, current stock availability by dose, and international delivery timelines for your country. Browse the complete tirzepatide injection range at Mediaid Pharmacy to confirm all available strengths and products before placing an order.
Order Wikijet (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.